[177Lu]Lu-NeoB + capecitabine

[177Lu]Lu-NeoB + capecitabine is an investigational combination therapy under clinical evaluation for the treatment of metastatic breast cancer that is estrogen receptor-positive (ER+), human epidermal growth factor receptor-2 negative (HER2-), and gastrin releasing peptide receptor positive (GRPR+), particularly in patients who have progressed after prior endocrine therapy with a CDK4/6 inhibitor. [177Lu]Lu-NeoB is a radioligand therapy that targets GRPR on tumor cells, delivering targeted radiation via lutetium-177 to induce cytotoxicity while sparing healthy tissue. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) that acts as a chemotherapeutic agent and radiosensitizer by inhibiting thymidylate synthase after conversion to 5-FU in tumor tissues. The rationale for combining these agents lies in the potential synergistic effect between targeted radiotherapy and chemotherapy/radiosensitization, aiming to enhance anti-tumor efficacy in endocrine-resistant metastatic breast cancer[1][5][6].

Other names

Lutetium-177 NeoB + capecitabine177Lu-Lu-NeoB plus capecitabine